Table 1.
Numerical and percentage distribution of patients with MS undergoing AHSCT, according to demographic and clinical characteristics.
| Demographic and clinical variables | N | % |
|---|---|---|
| Female/male | 15/3 | 83.3%/16.7% |
| Mean age and SD at the beginning of the study (years) | 35.2 ± 9.1 | – |
| Mean time of education and SD (years) | 16.3 ± 3.4 | – |
| Disease duration (years) | 8.6 ± 5.5 | |
| Median EDSS score before AHSCT (IQR) | 6.0 (6.0–6.5) | |
| Previous DMT | ||
| Fingolimod | 8 | |
| Natalizumab | 8 | |
| Alemtuzumab | 1 | |
| Interferon-beta | 1 | |
AHSCT Autologous Haematopoietic Stem Cell Transplantation, EDSS Expanded Disability Status Scale, SD standard deviation, IQR interquartile range, DMT disease modifying treatment.